



PTO/SB/21 (01-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/626,681
		Filing Date	July 24, 2003
		First Named Inventor	Alanine
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	21237

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	Remarks Documents A1, B1 - B14 and C1 - C21
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual:	Dennis P. Tramaloni		
Signature:			
Date:	August 27, 2003		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date August 27, 2003

Typed or printed	Dennis P. Tramaloni	Date	August 27, 2003
Signature			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, ThomasLuebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge.

Group:

Serial No. 10/626,681, filed July 24, 2003
(Case Docket No. 21237)

Examiner:

For: BENZODIOXOLE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
August 27, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1, B1-B14, and C1-C21 listed on Form PTO-1449 are enclosed.

Serial No. 10/626,681
Filed: July 24, 2003

Consideration of all the documents cited on Form PTO-1449 is requested.


Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)
Dennis P. Tramaloni
(Reg. No. 28,542)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4475
Telefax: (973) 235-2363

133203



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/626,681
				Filing Date	July 24, 2003
				First Name Inventor	Alanine
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	21237

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5,624,941		Barth, et. al.	04-29-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	EP	658546		SANOFI-SYNTHELABO	06-21-1995	
	B2	EP	656354		SANOFI	06-07-1995	
	B3	EP	576357		SANOFI	06-07-1995	
	B4	EP	0216831		BIGADAN A/S, HOJBOGARD BIOGASTEKNOLOGI	08-04-1987	
	B5	WO	0224630		ELI LILLY & CO.	03-28-2002	
	B6	WO	0015609		MIGNANI	03-23-2000	
	B7	WO	0164634		AVENTIS PHARMA S.A.	09-07-2001	
	B8	WO	0228346		AVENTIS PHARMA S.A.	04-11-2002	
	B9	WO	0164632		AVENTIS PHARMA S.A.	09-07-2001	
	B10	WO	0164633		AVENTIS PHARMA S.A.	09-07-2001	
	B11	WO	0132663		SANOFI-SYNTHELABO	05-10-2001	
	B12	WO	0046209		SANOFI-SYNTHELABO	08-10-2000	
	B13	WO	9719063		SANOFI	05-29-1997	
	B14	WO	0158869		BRISTOL-MYERS SQUIBB CO.	08-16-2001	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>				Complete if Known	
				Application Number	10/626,681
				Filing Date	July 24, 2003
				First Name Inventor	Alanine
				Group Art Unit	
				Examiner Name	
Sheet	2		2	Attorney Docket Number	21237

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	D. Shire, et. al. J. Biol. Chem. 270 (8) (1995) 3726-31	
	C2	S. Munro, et. al. Nature 365 (1993) 61-61	
	C3	Y. Gaoni, et. al. J. Am. Chem. Soc, 86 (1964) 16	
	C4	R. Mechoulam (Ed.) in "Cannabinoids as therapeutic Agents", (1986), pp. 1-20, CRC Pr	
	C5	E.M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314	
	C6	R. G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664	
	C7	W.A. Devane, et. al. Science 258 (1992) 1946-9	
	C8	V. Di Marzo, et. al., Trends in Neuroscience 21 (12) (1998) 521-8	
	C9	A.C. Porter, C.C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60	
	C10	C.M. Williams, T.C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317	
	C11	C.C. Felder, et. al., Proc. Natl. Acad. Sci. USA 90 (16) (1993) 7656-7660	
	C12	G. Colombo, et. al., Life Sci. 63 (8) (1998) L113-PL117	
	C13	V. Di Marzo, et. al., Nature 410 (6830) 822-825	
	C14	F. Barth, et. al. "Cannabinoid antagonists: From research tools to potential new drugs", Abstracts of Papers, 222 nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001	
	C15	AAI; M. Pacheco, et. al. Exp. Ther. 257 (1) (1991) 170-183	
	C16	F.M. Casiano, et. al. NIDA Res. Monogr. 105 (1991) 295-6	
	C17	AM630, K. Hosohata, et. al. Life. Sci 61 (1997) 115-118	
	C18	R. Pertwee, et. al., Life Sci. 56 (23-24) (1995) 1949-55	
	C19	LY320135, C.C. Felder, et. al., J. Pharmacol. Exp. Ther. 284, (1) (1998) 291-297 disclosed in WO9602248	
	C20	M. Kanyonyo, et. al., Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236	
	C21	F. Ooms, et. al., J. Med. Chem. 45 (9) (2002) 1748-1756	

Examiner Signature		DATE CONSIDERED	
--------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

133204